MA28008A1 - Derives pyridyle et leur utilisation en tant qu'agents therapeutiques - Google Patents

Derives pyridyle et leur utilisation en tant qu'agents therapeutiques

Info

Publication number
MA28008A1
MA28008A1 MA28836A MA28836A MA28008A1 MA 28008 A1 MA28008 A1 MA 28008A1 MA 28836 A MA28836 A MA 28836A MA 28836 A MA28836 A MA 28836A MA 28008 A1 MA28008 A1 MA 28008A1
Authority
MA
Morocco
Prior art keywords
therapeutic agents
pyridyl derivatives
mammal
formula
pyridyl
Prior art date
Application number
MA28836A
Other languages
English (en)
French (fr)
Inventor
Melwyn Abreo
Daniel F Harvey
Heinz W Gschwend
Wenbao Li
Chi Tu
Rajender Kamboj
Michael D Winther
Vishnumurthy Kodumuru
Cindy J Hudson
Mikhail A Kondratenko
Shifeng Liu
Vandna Raina
Serguei Sviridov
Zaihui Zhang
Bagherzadeh Mehran Seid
Shaoyi Sun
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA28008A1 publication Critical patent/MA28008A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA28836A 2003-07-30 2006-02-27 Derives pyridyle et leur utilisation en tant qu'agents therapeutiques MA28008A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49111803P 2003-07-30 2003-07-30
US49111603P 2003-07-30 2003-07-30
US49134003P 2003-07-30 2003-07-30

Publications (1)

Publication Number Publication Date
MA28008A1 true MA28008A1 (fr) 2006-07-03

Family

ID=34119804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28836A MA28008A1 (fr) 2003-07-30 2006-02-27 Derives pyridyle et leur utilisation en tant qu'agents therapeutiques

Country Status (15)

Country Link
US (2) US7605161B2 (https=)
EP (2) EP2316825A1 (https=)
JP (1) JP4782008B2 (https=)
KR (1) KR20060036106A (https=)
AU (2) AU2004261267B9 (https=)
BR (1) BRPI0412352A (https=)
CA (1) CA2533900A1 (https=)
EC (1) ECSP066312A (https=)
ES (1) ES2397389T3 (https=)
IL (1) IL173398A0 (https=)
MA (1) MA28008A1 (https=)
NO (1) NO20060972L (https=)
SG (1) SG145700A1 (https=)
TN (1) TNSN06036A1 (https=)
WO (1) WO2005011656A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
MXPA06001202A (es) * 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
WO2006004200A1 (ja) * 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1827438B2 (en) * 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007005205A (es) 2004-10-29 2007-05-11 Kalypsys Inc Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
AU2005311534B2 (en) * 2004-12-03 2011-02-17 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as H3 antagonists
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1940815B1 (en) 2005-10-25 2018-08-15 Kalypsys, Inc. Salts of modulators of ppar and methods of treating metabolic disorders
EP1966183A4 (en) * 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
WO2007092435A2 (en) 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
WO2007136746A2 (en) * 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Macrocyclic compounds and their uses as stearoyl-coa desaturase
WO2007143597A2 (en) 2006-06-05 2007-12-13 Novartis Ag Organic compounds
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008096746A1 (ja) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
ATE488499T1 (de) 2007-08-08 2010-12-15 Graceway Pharmaceuticals Llc Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
WO2010028761A1 (de) * 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
CA2750564A1 (en) 2009-02-17 2010-08-26 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN102388052A (zh) * 2009-04-01 2012-03-21 诺瓦提斯公司 调节硬脂酰基-CoA去饱和酶的螺环衍生物
GB0907425D0 (en) * 2009-04-29 2009-06-10 Glaxo Group Ltd Compounds
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE
EP2475367A1 (en) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
HRP20170507T1 (hr) 2011-06-22 2017-06-02 Purdue Pharma Lp Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe
BR112014029365A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche inibidores seletivos de células indiferenciadas
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
MX2021005688A (es) * 2018-11-14 2021-07-07 Allinky Biopharma Compuestos de piridina sulfonamida para el tratamiento contra afecciones relacionadas con interleucina 1 beta.
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1704588A (en) * 1987-04-03 1988-11-02 Upjohn Company, The Amino-9,10-secosteroids
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US4994456A (en) * 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
JP2502824B2 (ja) 1991-03-13 1996-05-29 松下電器産業株式会社 平面型誘電体フィルタ
JP2503198Y2 (ja) 1991-06-17 1996-06-26 株式会社椿本チエイン 搬送方向に傾動可能なワ―ク回動ア―ムを具えたワ―ク搬送装置
AU761291B2 (en) * 1999-03-17 2003-05-29 Astrazeneca Ab Amide derivatives
WO2000061556A1 (en) * 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
WO2001043746A1 (en) * 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Medicinal composition
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
BR0109188A (pt) * 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
WO2003037862A1 (en) * 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
JP2005510564A (ja) * 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
OA12793A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
MXPA04010555A (es) * 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
EP1551811A1 (en) * 2002-10-17 2005-07-13 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
JP2004203871A (ja) * 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
MXPA06001202A (es) * 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
CN1829701A (zh) * 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途

Also Published As

Publication number Publication date
AU2004261267A1 (en) 2005-02-10
WO2005011656A3 (en) 2005-05-06
AU2004261267B2 (en) 2009-02-12
BRPI0412352A (pt) 2006-09-05
SG145700A1 (en) 2008-09-29
KR20060036106A (ko) 2006-04-27
US8153636B2 (en) 2012-04-10
NO20060972L (no) 2006-05-02
US20060199802A1 (en) 2006-09-07
JP4782008B2 (ja) 2011-09-28
ECSP066312A (es) 2006-07-28
TNSN06036A1 (en) 2007-10-03
CA2533900A1 (en) 2005-02-10
WO2005011656A2 (en) 2005-02-10
JP2007500719A (ja) 2007-01-18
EP1651606A2 (en) 2006-05-03
IL173398A0 (en) 2006-06-11
US20100048584A1 (en) 2010-02-25
ES2397389T3 (es) 2013-03-06
AU2004261267B9 (en) 2009-04-09
AU2009201861A1 (en) 2009-06-04
AU2009201861A8 (en) 2009-06-11
EP1651606B1 (en) 2012-10-24
US7605161B2 (en) 2009-10-20
EP2316825A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
MA28012A1 (fr) Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MA26877A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
TNSN06033A1 (en) Piperazine derivatives and their use as therapeutic agents
PA8591701A1 (es) Derivados de pirrolopirimidina
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DE69829861D1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
MA27291A1 (fr) Acides phenoxyacetiques substitues
ATE245151T1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung